We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
ALTUVIIIO Sanofi-Aventis Australia Pty Ltd
Product name
ALTUVIIIO
Sponsor
Accepted date
Jul-2025
Active ingredients
efanesoctocog alfa
Proposed indication
Altuviiio (efanesoctocog alfa) is a long-acting treatment for people with haemophilia A (a bleeding disorder caused by low levels of clotting factor VIII). It’s suitable for adults, teens, and children.
It is proposed for
-prevention or reduction in bleeding episodes through regular use,
-treating and stopping bleeding when it happens, and
-managing bleeding during surgery
It is proposed for
-prevention or reduction in bleeding episodes through regular use,
-treating and stopping bleeding when it happens, and
-managing bleeding during surgery
Application type
A (new medicine)
Publication date
Jul-2025
Orphan drug
Sponsors receive a fee waiver to help bring medicines for a small population to market.